Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Logo
PCVX US​

Vaxcyte, Inc.(PCVX US)

$60.43-2.423.85%Ext:$63.66+3.235.35%(Market Closed · 00:00:02 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Vaxcyte, Inc. — Company Profile

Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.

Sector
Materials
Industry
Paper & Forest Products
Exchange
UQ
CEO
Grant E. Pickering
Headquarters
San Carlos, CA, US
IPO Date
Jun 12, 2020
Employees
507
Website
vaxcyte.com

Key Metrics

Price
$56.48
Market Cap
$8.16B
Revenue (TTM)
$0.00
Net Income (TTM)
$-320622000.00
EPS (TTM)
-2.30
P/E (TTM)
-8.62
P/B (TTM)
2.72
Dividend Yield
0.00%
ROE (TTM)
-10.70%
ROA (TTM)
-9.58%
Operating Margin
0.00%
Beta
0.77

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.

Website
vaxcyte.com
Location
San Carlos, CA, US
Phone650 837 0111
Employees507
CEOGrant E. Pickering
Sector
Materials
Industry
Paper & Forest Products
IPO DateJun 12, 2020

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(757)

Expand
  • 8-KEntry into a Material Definitive Agreement9 Oct
  • 424B5Prospectus filing (Rule 424(b)(5))8 Oct
  • 424B5Prospectus filing (Rule 424(b)(5))8 Oct
  • 4Statement of changes in beneficial ownership7 Oct
  • 4Statement of changes in beneficial ownership7 Oct
  • FWPFree writing prospectus7 Oct
  • 305B2Application for qualification of indenture5 Oct
  • 424B5Prospectus filing (Rule 424(b)(5))5 Oct
  • 424B5Prospectus filing (Rule 424(b)(5))5 Oct
  • 144Cowan Elvia5 Oct
  • 144Wassil Jim5 Oct
  • 8-KVaxcyte Reports Positive Topline Data fromOPUS-1,the Pivotal Adult Phase 35 Oct
  • 4Statement of changes in beneficial ownership2 Oct
  • 144Wassil Jim1 Oct
  • 4Statement of changes in beneficial ownership9 Sep
  • 4Statement of changes in beneficial ownership9 Sep
  • 4Statement of changes in beneficial ownership9 Sep
  • 4Statement of changes in beneficial ownership9 Sep
  • 4Statement of changes in beneficial ownership9 Sep
  • 4Statement of changes in beneficial ownership9 Sep

News

  • Vaxcyte, Inc. (NASDAQ:PCVX) Stock Rated “Moderate Buy” by Sell-Side Brokerages18 Oct
  • Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet14 Oct
  • Vaxcyte (NASDAQ: PCVX) raises $575 million with notes and stock sale12 Oct
  • Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 18,000 Shares of Company Stock8 Oct
  • Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes6 Oct
  • Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 20276 Oct
  • Vaxcyte (NASDAQ:PCVX) Sees Large Volume Increase Following Analyst Upgrade6 Oct
  • Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial6 Oct
  • Vaxcyte's VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial5 Oct
  • Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes5 Oct
  • Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript5 Oct
  • Vaxcyte shares surge on late-stage vaccine trial success5 Oct
  • Vaxcyte (NASDAQ:PCVX) Stock Sees Heavy Call Option Buying5 Oct
  • Vaxcyte Stock Spikes 57% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck5 Oct
  • Vaxcyte (NASDAQ:PCVX) Reaches New 52-Week High – Here’s Why5 Oct
  • Vaxcyte Stock Hits New 52-Week High - Here's Why5 Oct
  • Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate5 Oct
  • Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate4 Oct
  • 4 Biotech Stocks With Key Clinical Readouts Expected This Fall22 Sep
  • California State Teachers Retirement System Has $475.89 Million Stake in Vaxcyte, Inc. $PCVX15 Sep

Mentions in Filings

  • … ptember 2017. Dr. Hopfner currently serves as a board member of Evommune, Inc., and on the boards of directors of a number of private life sciences companies. Dr. Hopfner previously served on the board of directors of <strong>Vaxcyte, Inc.</strong>, Oculis Holding AG and Inozyme Pharma Inc. Dr. Hopfner received a B.Sc. in Pharmacy and a Ph.D. in Pharmacology from the University of Saskatchewan and an M.B.A. from the University of Chicago. We believe Dr. Hopfner i …
    Rallybio CorpVaxcyte, Inc.·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·15 Oct
  • … herapeutics, Inc., a biotechnology company, and several privately held companies. He previously served on the boards of directors of CymaBay Therapeutics, Inc. until April 2024, CRISPR Therapeutics AG until June 2019, <strong>Vaxcyte, Inc.</strong> until June 2022, and Vera 180 --- Table of Contents Therapeutics, Inc. until May 2022. Mr. von Emster holds a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Finan …
    Iambic Therapeutics, Inc.Vaxcyte, Inc.·424B4 - Prospectus filing (Rule 424(b)(4))·Q4 26·15 Oct
  • … ptember 2017. Dr. Hopfner currently serves as a board member of Evommune, Inc., and on the boards of directors of a number of private life sciences companies. Dr. Hopfner previously served on the board of directors of <strong>Vaxcyte, Inc.</strong>, Oculis Holding AG and Inozyme Pharma Inc. Dr. Hopfner received a B.Sc. in Pharmacy and a Ph.D. in Pharmacology from the University of Saskatchewan and an M.B.A. from the University of Chicago. We believe Dr. Hopfner i …
    Rallybio CorpVaxcyte, Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·14 Oct
  • … udes Slate Medicines (under agreement to reverse merge onto Nasdaq), Kailera Therapeutics (Nasdaq: KLRA), Palvella Therapeutics (Nasdaq: PVLA), Tarsus Pharmaceuticals (Nasdaq: TARS), Mirum Pharmaceuticals (Nasdaq: MIRM), <strong>Vaxcyte</strong> (Nasdaq: PCVX), and Imago BioSciences (Nasdaq: IMGO; acquired by Merck for $1.35 billion). Other notable public company investments made by FLS as of August 31, 2026, include those in Erasca (Nasdaq: ERAS), Trevi Therape …
    Frazier Life Sciences Acquisition Corp. IIVaxcyte, Inc.·424B4 - Prospectus filing (Rule 424(b)(4))·Q4 26·14 Oct
  • … n was acquired by Daiichi Sankyo in 2011. Dr. Hirth currently serves on the board of directors of Aligos Therapeutics, IO Biotech, Inc., and several private companies. He previously served on the board of directors of <strong>Vaxcyte, Inc.</strong> from January 2017 to April 2025. Dr. Hirth holds an MSc and PhD in Molecular Genetics from Heidelberg University, Germany and completed his post-doctoral work at the University of California, San Diego. We believe that …
    TRex Bio, Inc.Vaxcyte, Inc.·424B4 - Prospectus filing (Rule 424(b)(4))·Q4 26·9 Oct
  • … herapeutics, Inc., a biotechnology company, and several privately held companies. He previously served on the boards of directors of CymaBay Therapeutics, Inc. until April 2024, CRISPR Therapeutics AG until June 2019, <strong>Vaxcyte, Inc.</strong> until June 2022, and Vera 181 --- Table of Contents Therapeutics, Inc. until May 2022. Mr. von Emster holds a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Finan …
    Iambic Therapeutics, Inc.Vaxcyte, Inc.·S-1/A - Registration statement (general form, amendment)·Q4 26·8 Oct

Key Stats

Trading

Px/Chg 1D$56.48 / +0.77%
Avg Volume1.50M
Beta0.77
Mkt Cap8.16B
FD Mkt Cap8.60B

Float

Shrs Out/Float144.40M / 132.08M
Short Float0.13%
Days to Cover6.91
Stock Repurchased$0.00

Current Valuation

EV8.01B
EV/EBITDA-8.70
EV/Sales0.00
P/B2.72
P/S0.00
FCF Yield-3.62%
ROE-10.70%
ROA-9.58%
Current Ratio7.49

Estimates

P/E-8.62
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-19.01-14.92-16.31-7.69-30.72-25.44
Price / Sales0.000.000.000.000.000.00
Price / Book Value3.083.505.291.082.822.72
Price / Free Cash Flow-21.31-18.90-17.99-7.51-34.53-27.61
ENTERPRISE VALUE METRICS
Enterprise Value5,519.62,518.06,191.93,250.47,626.98,011.0
Enterprise Value / Sales0.000.000.000.000.000.00
Enterprise Value / EBITDA-18.56-11.76-15.79-7.25-32.51-25.45
Enterprise Value / EBIT-17.92-11.27-15.39-7.01-30.94-24.99

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue—-----
Gross Income—-----
EBITDA66.5%-96.6-214.0-392.1-448.1-741.8
EBIT66.4%-100.1-223.5-402.3-463.9-766.6
Net Income66.4%-100.1-223.5-402.3-463.9-766.6
EPS (Diluted)30.7%-1.93-3.44-4.14-3.80-5.63
BALANCE SHEET
Cash & ST Inv58.7%246.0931.41,080.21,747.21,561.0
Total Assets75.1%324.31,006.21,407.93,511.33,046.0
Total Liabilities72.9%40.352.6167.4205.5360.5
Total Shareholder Equity75.4%284.0953.61,240.53,305.82,685.5
CASH FLOW
Net Operating Cash Flow52.4%-121.4-170.6-296.8-452.6-655.6
Cap Ex20.3%-6.6-5.8-67.9-22.4-13.7
Free Cash Flow51.2%-127.9-176.4-364.7-475.1-669.3

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)60.43
Basic Shares144.40
Market Cap8,726.0
Diluted Shares139.51
Fully Diluted Shares Outstanding139.51
Fully Diluted Market Cap8,430.4
+Consolidated Debt116.3
−In-the-Money Convertible Debt—
+Capital Leases110.2
+Operating Leases—
−Cash & Equivalents-260.8
−Short-term Investments-1,476.3
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value8,581.4

Segment data

Revenue

by Products and services

  • Pneumococcal Conjugate Vaccine100%

Related companies

Amgen Inc

AMGN US

Gilead Sciences, Inc.

GILD US

Intuitive Surgical Inc

ISRG US

Moderna, Inc.

MRNA US

Argenx Se

ARGX US

Edwards Lifesciences Corporation

EW US

Revolution Medicines, Inc.

RVMD US

Biogen Inc.

BIIB US

BioNTech SE

BNTX US

STERIS plc

STE US

Nordson Corp

NDSN US

Tyson Foods, Inc.

TSN US